Healthcare Improvement Scotland | SMC Advice on new medicines

Product update
SMC2406

# bempedoic acid / ezetimibe 180mg / 10mg film-coated tablets (Nustendi®)

Daiichi Sankyo UK Ltd

10 September 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE**: following an abbreviated submission

**bempedoic acid / ezetimibe (Nustendi®)** is accepted for restricted use within NHSScotland.

**Indication under review:** in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

- in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
- alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone
- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.

**SMC restriction:** for use in patients who are:

- statin intolerant or for whom a statin is contra-indicated and
- where ezetimibe alone does not appropriately control LDL-C and
- where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate

SMC has previously accepted bempedoic acid for restricted use in combination with ezetimibe for this indication. Nustendi® (bempedoic acid / ezetimibe) provides a single tablet alternative to bempedoic acid plus ezetimibe.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**
**Scottish Medicines Consortium**